175 related articles for article (PubMed ID: 19102717)
21. Pharmacogenetics in pancreatic cancer.
Tourkantonis IS; Peponi E; Syrigos KN; Saif MW
JOP; 2014 Jul; 15(4):335-9. PubMed ID: 25076337
[TBL] [Abstract][Full Text] [Related]
22. Phase II pharmacogenomics-based adjuvant therapy trial in patients with non-small-cell lung cancer: Southwest Oncology Group Trial 0720.
Bepler G
Clin Lung Cancer; 2007 Sep; 8(8):509-11. PubMed ID: 17948610
[No Abstract] [Full Text] [Related]
23. Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer.
Thatcher N; Jayson G; Bradley B; Ranson M; Anderson H
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-6-S8-12. PubMed ID: 9207309
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective.
Ciccolini J; Serdjebi C; Peters GJ; Giovannetti E
Cancer Chemother Pharmacol; 2016 Jul; 78(1):1-12. PubMed ID: 27007129
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R
Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311
[TBL] [Abstract][Full Text] [Related]
26. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
Liu XQ; Wang WX; Lin L; Song ST
Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
[TBL] [Abstract][Full Text] [Related]
27. Impact of biomarkers on non-small cell lung cancer treatment.
Toschi L; Cappuzzo F
Target Oncol; 2010 Mar; 5(1):5-17. PubMed ID: 20443070
[TBL] [Abstract][Full Text] [Related]
28. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
Davidson JD; Ma L; Flagella M; Geeganage S; Gelbert LM; Slapak CA
Cancer Res; 2004 Jun; 64(11):3761-6. PubMed ID: 15172981
[TBL] [Abstract][Full Text] [Related]
29. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
[TBL] [Abstract][Full Text] [Related]
30. Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
Mercier C; Dahan L; Ouafik L; André N; Ciccolini J
Eur J Clin Pharmacol; 2010 Sep; 66(9):959-60. PubMed ID: 20563566
[No Abstract] [Full Text] [Related]
31. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Tibaldi C; Giovannetti E; Vasile E; Mey V; Laan AC; Nannizzi S; Di Marsico R; Antonuzzo A; Orlandini C; Ricciardi S; Del Tacca M; Peters GJ; Falcone A; Danesi R
Clin Cancer Res; 2008 Mar; 14(6):1797-803. PubMed ID: 18347182
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
Mazzoni F; Cecere FL; Meoni G; Giuliani C; Boni L; Camerini A; Lucchesi S; Martella F; Amoroso D; Lucherini E; Torricelli F; Di Costanzo F
Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions.
Gautschi O; Mack PC; Davies AM; Jablons DM; Rosell R; Gandara DR
Clin Lung Cancer; 2008; 9 Suppl 3():S129-38. PubMed ID: 19419927
[TBL] [Abstract][Full Text] [Related]
34. Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer.
Yuan ZJ; Zhou WW; Liu W; Wu BP; Zhao J; Wu W; He Y; Yang S; Su J; Luo Y
Asian Pac J Cancer Prev; 2015; 16(10):4347-51. PubMed ID: 26028097
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?
Giovannetti E; Toffalorio F; De Pas T; Peters GJ
Pharmacogenomics; 2012 Jul; 13(9):1073-86. PubMed ID: 22838953
[TBL] [Abstract][Full Text] [Related]
36. Intrathecal gemcitabine chemotherapy for non-small cell lung cancer patients with meningeal carcinomatosis--a case report.
Chen YM; Chen MC; Tsai CM; Perng RP
Lung Cancer; 2003 Apr; 40(1):99-101. PubMed ID: 12660014
[TBL] [Abstract][Full Text] [Related]
37. The promise of pharmacogenomics: gemcitabine and pemetrexed.
Rosell R; Taron M; Sanchez JM; Moran T; Reguart N; Besse B; Isla D; Massuti B; Alberola V; Sanchez JJ
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):70-6. PubMed ID: 15655942
[TBL] [Abstract][Full Text] [Related]
38. The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.
Nie X; Cheng G; Ai B; Zhang S
Cancer Biomark; 2013 Jan; 13(6):433-40. PubMed ID: 24595080
[TBL] [Abstract][Full Text] [Related]
39. Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
Kroep JR; van Moorsel CJ; Veerman G; Voorn DA; Schultz RM; Worzalla JF; Tanzer LR; Merriman RL; Pinedo HM; Peters GJ
Adv Exp Med Biol; 1998; 431():657-60. PubMed ID: 9598147
[No Abstract] [Full Text] [Related]
40. Gemcitabine in non-small cell lung cancer.
Sørensen JB
Lung Cancer; 1995 Apr; 12 Suppl 1():S173-5. PubMed ID: 7551926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
